SG10201700334XA - Composition useful for the prevention or reduction of the progression of prostate cancer - Google Patents

Composition useful for the prevention or reduction of the progression of prostate cancer

Info

Publication number
SG10201700334XA
SG10201700334XA SG10201700334XA SG10201700334XA SG10201700334XA SG 10201700334X A SG10201700334X A SG 10201700334XA SG 10201700334X A SG10201700334X A SG 10201700334XA SG 10201700334X A SG10201700334X A SG 10201700334XA SG 10201700334X A SG10201700334X A SG 10201700334XA
Authority
SG
Singapore
Prior art keywords
progression
prevention
reduction
prostate cancer
composition useful
Prior art date
Application number
SG10201700334XA
Inventor
Franco Gaetani
Ashraf Virmani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SG10201700334XA publication Critical patent/SG10201700334XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SG10201700334XA 2008-07-31 2009-07-24 Composition useful for the prevention or reduction of the progression of prostate cancer SG10201700334XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161516 2008-07-31

Publications (1)

Publication Number Publication Date
SG10201700334XA true SG10201700334XA (en) 2017-03-30

Family

ID=39967972

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013054226A SG192527A1 (en) 2008-07-31 2009-07-24 Composition useful for the prevention or reduction of the progression of prostate cancer
SG10201700334XA SG10201700334XA (en) 2008-07-31 2009-07-24 Composition useful for the prevention or reduction of the progression of prostate cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013054226A SG192527A1 (en) 2008-07-31 2009-07-24 Composition useful for the prevention or reduction of the progression of prostate cancer

Country Status (20)

Country Link
US (2) US8758835B2 (en)
EP (1) EP2310023B1 (en)
JP (1) JP5564499B2 (en)
KR (1) KR101621910B1 (en)
CN (1) CN102112141B (en)
AU (1) AU2009276035B2 (en)
BR (1) BRPI0916435A8 (en)
CA (1) CA2732205C (en)
DK (1) DK2310023T3 (en)
EA (1) EA019814B1 (en)
ES (1) ES2602834T3 (en)
HK (1) HK1158076A1 (en)
HR (1) HRP20161447T1 (en)
HU (1) HUE031821T2 (en)
MX (1) MX2011000941A (en)
MY (1) MY160546A (en)
PL (1) PL2310023T3 (en)
PT (1) PT2310023T (en)
SG (2) SG192527A1 (en)
WO (1) WO2010012651A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2982460B1 (en) 2011-11-14 2016-08-05 Virbac Sa ORAL ADMINISTRATION PRODUCTS COMPRISING PUNICA GRANATUM GRANITE EXTRACTS FOR ANIMAL PET AND ITS APPLICATIONS
CN102652778A (en) * 2012-03-29 2012-09-05 武汉华大药业有限公司 Medicinal composition
CN105796803A (en) * 2014-12-30 2016-07-27 青岛加云华海健康科技有限公司 Traditional Chinese medicine composition for treating and preventing prostatic diseases and its preparation method and use
CN108451979B (en) * 2018-06-28 2020-04-28 新疆金骏阳光生物科技有限公司 Lycopene compound preparation with auxiliary treatment effect on prostate cancer and application thereof
KR102514074B1 (en) 2022-08-10 2023-03-27 (주)스마트푸릇 Fermented pomegranate composition for improving vascular health, prostate or sexual function, containing high content of ellagic acid and gallic acid with increased absorption into the body and its use having skin whitening, wrinkle improvement or antioxidant function, and method for manufacturing the same by using EFC method

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030622A (en) * 1998-06-23 2000-02-29 Shehadeh; Ahmad Abdallah Herbal extract composition and method with immune-boosting capability
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
FR2791573B1 (en) * 1999-03-30 2003-04-11 Pf Medicament USE OF A SERENOA REPENS EXTRACT FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF PROSTATE CANCER
US6818234B1 (en) * 1999-08-27 2004-11-16 Access Business Group International Llc Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation
DE20009840U1 (en) * 2000-05-31 2000-08-24 Phyt-Immun GmbH, 66424 Homburg Food supplements, pharmaceuticals or pharmaceutical ingredients, each containing a shallot / oil macerate
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
US8337914B2 (en) * 2002-02-27 2012-12-25 Access Business Group International Llc Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation
KR20030087566A (en) * 2002-05-07 2003-11-14 액세스 비지니스 그룹 인터내셔날 엘엘씨 Phytonutrient Nutritional Supplement
US6572899B1 (en) * 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
US20060251750A1 (en) * 2002-09-30 2006-11-09 Tabor Aaron T Soy formulations and their use in skin care
US8357945B2 (en) * 2002-12-27 2013-01-22 Momentive Performance Materials Inc. Gallium nitride crystal and method of making same
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
WO2005058232A2 (en) * 2003-12-11 2005-06-30 Tercica, Inc. Methods and compositions for the treatment of prolactin-receptor related disorders
US20050261367A1 (en) * 2004-03-29 2005-11-24 Howard Murad Methods for treating dermatological and other health-related conditions in a patient
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
CA2603863A1 (en) * 2005-04-07 2006-10-19 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
DE202005020103U1 (en) * 2005-12-23 2006-04-27 China Vital Med E.K. Food auxiliary agent, useful for preventing prostate complaints, comprises pomegranate flour, pomegranate extract, rye powder, agraricus-agaric powder, rosemary powder, saw palmetto extract, white tea extract and curcumin extract
US20080031979A1 (en) * 2006-08-04 2008-02-07 Claude Saliou Use of extracts for the treatment of viral disorders
CN101646433B (en) * 2006-10-24 2011-11-16 戴维·W·克雷姆平 Anti-resorptive and bone building dietary supplements and methods of use
US7927633B2 (en) * 2008-03-28 2011-04-19 Janiece Diane Swilling Adaptogenic tea

Also Published As

Publication number Publication date
CA2732205A1 (en) 2010-02-04
HUE031821T2 (en) 2017-08-28
JP2011529465A (en) 2011-12-08
ES2602834T3 (en) 2017-02-22
PT2310023T (en) 2016-11-22
US20110262417A1 (en) 2011-10-27
MX2011000941A (en) 2011-03-29
DK2310023T3 (en) 2016-12-12
US8758835B2 (en) 2014-06-24
HK1158076A1 (en) 2012-07-13
KR101621910B1 (en) 2016-05-17
EA201170269A1 (en) 2011-06-30
EP2310023B1 (en) 2016-10-12
AU2009276035A1 (en) 2010-02-04
EA019814B1 (en) 2014-06-30
WO2010012651A2 (en) 2010-02-04
AU2009276035B2 (en) 2015-10-01
US9084812B2 (en) 2015-07-21
BRPI0916435A8 (en) 2017-12-26
US20140255512A1 (en) 2014-09-11
EP2310023A2 (en) 2011-04-20
CN102112141A (en) 2011-06-29
KR20110043615A (en) 2011-04-27
MY160546A (en) 2017-03-15
BRPI0916435A2 (en) 2016-02-16
PL2310023T3 (en) 2017-02-28
HRP20161447T1 (en) 2016-12-16
SG192527A1 (en) 2013-08-30
CA2732205C (en) 2018-01-02
CN102112141B (en) 2013-03-06
WO2010012651A3 (en) 2010-04-01
JP5564499B2 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
EP2303021A4 (en) Compounds for the treatment of cancer
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2310526A4 (en) Compositions for the detection and treatment of colorectal cancer
ZA201107879B (en) Composition for the treatment of prostate cancer
EP2340027A4 (en) Methods and compositions for the treatment of cancer
HK1158535A1 (en) Suppression of cancer
EP2049151A4 (en) Methods and compositions for the treatment of cancer
IL214349A0 (en) Compositions and methods for the treatment of cancer
IL238394B (en) Compositions comprising combination of agents for cancer treatment
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
EP1908459A4 (en) Composition for prevention of cancer
EP2437738A4 (en) Methods and compositions for the treatment of cancer
EP2150270A4 (en) Methods and compositions for the treatment of cancer
HK1254607A1 (en) Organoarsenic compound for the treatment of cancer
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
SG10201700334XA (en) Composition useful for the prevention or reduction of the progression of prostate cancer
IL206189A0 (en) Compound for use in the treatment of cancer
EP2473506A4 (en) Compounds and compositions for treating cancer
EP2352501A4 (en) Compounds for the treatment of osteoporosis and cancers
EP2411031A4 (en) Methods and compositions for the treatment of cancer
IL209005A0 (en) Use of corticotropin-releasing factor for the treatment of cancer
EP2115464A4 (en) Methods and compositions for determining the efficacy of breast cancer therapeutics
GB0822018D0 (en) Prevention of metastatic cancer
AU2008905198A0 (en) Compositions and Methods for the Prevention and Treatment of Cancer